Pediatric Drugs

, Volume 14, Issue 6, pp 377–387

Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia

Current and Emerging Treatments
Review Article

DOI: 10.1007/BF03262418

Cite this article as:
Martin, A., Morgan, E. & Hijiya, N. Pediatr Drugs (2012) 14: 377. doi:10.1007/BF03262418

Abstract

Relapsed acute lymphoblastic leukemia (ALL) represents a major cause of morbidity and mortality in pediatrics. With contemporary chemotherapy, >85% of patients with newly diagnosed ALL survive. Unfortunately, 20% of these patients will relapse and for these children, outcomes remain poor despite our best known chemotherapy protocols. Most of these children will achieve a second complete remission, but maintaining this remission remains difficult. Because relapsed ALL is such a significant cause of morbidity and mortality, it is the focus of much research interest. Efforts have been made and continue to focus on understanding the underlying biology that drives relapse. The role of hematopoietic stem cell transplantation in relapsed ALL remains unclear, but many clinicians still favor this for high-risk patients given the poor prognosis with current chemotherapy alone.

It is important to use new drugs with little cross-resistance in the treatment of relapsed ALL. New classes of agents are currently being studied. We also discuss prognostic factors and the biology of relapsed ALL.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.Division of Hematology/Oncology/Stem Cell TransplantAnn & Robert H. Lurie Children’s Hospital of ChicagoChicagoUSA
  2. 2.Department of Pediatrics, Feinberg School of MedicineNorthwestern UniversityChicagoUSA

Personalised recommendations